Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 26

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

241

HTML

1916

Figures (1-3)

220

Tables (1-3)

186

Sum=2563

Jul 14, 2005 (publication date) through Nov 7, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Jul 14, 2005; 11(26): 3980-3984
Published online Jul 14, 2005. doi: 10.3748/wjg.v11.i26.3980

Table 1 Inhibition of proliferation by LDM, MMC, ADM and the LDM constituents LDC and LDP in hepatoma cells (mean±SD)

LDM: lidamycin; LDC: LDM enediyne chromophore; LDP: LDM apoprotein; ADM: adriamycin, MMC: mitomycin C.

Citation: Huang YH, Shang BY, Zhen YS. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J Gastroenterol 2005; 11(26): 3980-3984
URL: https://www.wjgnet.com/1007-9327/full/v11/i26/3980.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i26.3980